Reagent update
Current availability from NIBSC of candidate influenza vaccine viruses, SRD reagents and neuraminidase reagents for use in the 2023-24 Northern hemisphere season and 2023 Southern hemisphere season (See below for pricing information).
More information can be found in the Influenza Resource Centre pages
Update 151 - 28 February 2023
Candidate influenza viruses for use in the Northern hemisphere 2023-241
Candidate influenza vaccine viruses
|
NIBSC code
|
|
H1N1
|
|
|
A/Victoria/4879/2022
|
22/316
|
|
IVR-238 ressortant derived from A/Victoria/4879/2022
|
22/318
|
|
H3N2
|
|
|
A/Darwin/9/2021
|
21/214
|
|
NIB-126 reassortant derived from A/Darwin/9/2021
|
21/228
|
|
IVR-228 reassortant derived from A/Darwin/9/2021
|
21/246
|
|
X-369A ressortant derived from A/Darwin/9/2021
|
21/384
|
|
SAN-010 reassortant derived from A/Darwin/9/2021
|
21/306
|
|
A/Darwin/6/2021
|
21/212
|
|
NIB-127 reassortant derived from A/Darwin/6/2021
|
21/226
|
|
IVR-227 reassortant derived from A/Darwin/6/2021
|
21/204
|
|
X-367A reassortant derived from A/Darwin/6/2021
|
21/382
|
|
A/Michigan/173/2020
|
21/298
|
|
B (Victoria lineage)
|
|
|
B/Austria/1359417/2021
|
21/224
|
|
BVR-26 reassortant derived from B/Austria/1359417/2021
|
21/218
|
|
B/Michigan/01/2021
|
21/244
|
|
B/Singapore/WUH4618/2021
|
21/242
|
|
B/Guangdong-Zhenjiang/1516/2021
|
21/388
|
|
B (Yamagata lineage)
|
|
|
B/Phuket/3073/2013 wild type virus
|
21/132
|
|
B/Brisbane/9/2014 wild type virus
|
21/352
|
|
B/Utah/9/2014 wild type virus
|
14/320 & 21/348
|
|
NYMC BX-57 reassortant derived from
B/Hong Kong/3417/2014
|
20/134
|
|
NYMC BX-59A reassortant derived from B/California/12/2015
|
15/274 & 21/350
|
|
NYMC BX-59B reassortant derived from B/California/12/2015
|
15/294
|
|
NYMC BX-63 reassortant derived from B/Arizona/10/2015
|
17/124
|
|
NYMC BX-63A reassortant derived from B/Arizona/10/2015
|
17/126
|
1Recommendations announced for influenza vaccine composition for the 2023-2024 northern hemisphere influenza season (who.int)
Candidate influenza viruses for use in the Northern hemisphere 2023-241
Reagents for influenza vaccine standardisation
|
NIBSC code
|
|
H1N1
|
|
|
Antigen
|
To de defined
|
|
Antiserum
|
To be defined
|
|
H3N2
|
|
|
A/Darwin/9/2021 (SAN-010) antigen
|
21/320
|
|
A/Darwin/9/2021 (IVR-228) antigen
|
21/318
|
|
A/Darwin/6/2021 (IVR-227) antigen
|
21/314
|
|
A/Darwin/9/2021 - like antiserum
|
21/324
|
|
B (Victoria lineage)
|
|
|
B/Austria/1359417/2021 (BVR-26) antigen
|
21/316
|
|
B/Michigan/01/2021 antigen
|
21/330
|
|
B/Austria/1359417/2021 - like antiserum
|
21/326
|
|
B (Yamagata lineage)
|
|
|
B/Phuket/3073/2013 antigen
|
21/136
|
|
B/Utah/9/2014 (cell derived) antigen
|
15/100
|
|
B/Singapore/INFTT-16-0610/2016 (cell derived) antigen
|
19/308
|
|
B/Phuket/3073/2013 - like antiserum
|
19/322
|
1Recommendations announced for influenza vaccine composition for the 2023-2024 northern hemisphere influenza season (who.int)
Neuraminidase reagents
|
NIBSC code
|
|
N1
|
|
|
NA antiserum prepared from A/California/7/2009
|
10/218
|
|
NA antiserum prepared from A/New Caledonia/20/99
|
04/230
|
|
N2
|
|
|
NA antiserum prepared from A/Victoria/361/2011
|
14/144
|
|
NA antiserum prepared from A/South Australia/34/2019
|
19/320
|
|
B
|
|
|
NA antiserum prepared from B/Jiangsu/10/2003
|
04/228
|
|
NA antiserum prepared from B/Malaysia/2506/2004
|
05/252
|
|
NA antiserum prepared for B/Florida/4/2006
|
09/316
(please contact for availability)
|
|
NA antiserum prepared from B/Phuket/3073/2013
|
21/322
|
Candidate influenza viruses for use in the Southern hemisphere 20232
Candidate influenza vaccine viruses
|
NIBSC code
|
|
H1N1
|
|
|
A/Sydney/5/2021
|
22/200
|
|
SAN-013 reassortant derived from A/Sydney/5/2021
|
22/142
|
|
CBER-48A reassortant derived from A/Sydney/5/2021
|
22/214
|
|
IVR-235 reassortant derived from A/Sydney/175/2022
|
22/234
|
|
H3N2
|
|
|
A/Darwin/9/2021
|
21/214
|
|
NIB-126 reassortant derived from A/Darwin/9/2021
|
21/228
|
|
IVR-228 reassortant derived from A/Darwin/9/2021
|
21/246
|
|
X-369A ressortant derived from A/Darwin/9/2021
|
21/384
|
|
SAN-010 reassortant derived from A/Darwin/9/2021
|
21/306
|
|
A/Darwin/6/2021
|
21/212
|
|
NIB-127 reassortant derived from A/Darwin/6/2021
|
21/226
|
|
IVR-227 reassortant derived from A/Darwin/6/2021
|
21/204
|
|
X-367A reassortant derived from A/Darwin/6/2021
|
21/382
|
|
A/Michigan/173/2020
|
21/298
|
|
B (Victoria Lineage)
|
|
|
B/Austria/1359417/2021
|
21/224
|
|
BVR-26 reassortant derived from B/Austria/1359417/2021
|
21/218
|
|
B/Michigan/01/2021
|
21/244
|
|
B/Singapore/WUH4618/2021
|
21/242
|
|
B/Guangdong-Zhenjiang/1516/2021
|
21/388
|
|
B (Yamagata lineage)
|
|
|
B/Phuket/3073/2013 wild type virus
|
21/132
|
|
B/Brisbane/9/2014 wild type virus
|
21/352
|
|
B/Utah/9/2014 wild type virus
|
14/320 & 21/348
|
|
NYMC BX-57 reassortant derived from
B/Hong Kong/3417/2014
|
20/134
|
|
NYMC BX-59A reassortant derived from B/California/12/2015
|
15/274 & 21/350
|
|
NYMC BX-59B reassortant derived from B/California/12/2015
|
15/294
|
|
NYMC BX-63 reassortant derived from B/Arizona/10/2015
|
17/124
|
|
NYMC BX-63A reassortant derived from B/Arizona/10/2015
|
17/126
|
2New recommendations for the composition of influenza vaccines in 2023 for the southern hemisphere (who.int)
SRD reagents for use in the Southern hemisphere 20232
(For H3N2 subtype and B Victoria and Yamagata lineage reagents please see tables for Northern hemisphere 2023-2024 above)
Reagents for influenza vaccine standardisation
|
NIBSC code
|
|
H1N1
|
|
|
A/Victoria/2570/2019 (IVR-215) antigen
|
22/100
|
|
A/Victoria/2570/2019 - like antiserum
|
21/210
|
2New recommendations for the composition of influenza vaccines in 2023 for the southern hemisphere (who.int)
Pricing information
Viruses are free of charge (normally a maximum of two vials per recipient), but customers are expected to pay shipping and packing costs. Reagents for Single Radial Diffusion assay are subject to a handling fee as stated on the product information page, plus shipping and packing costs. Approved National Control Laboratories for human health are exempt from the handling fee.
Calibration of Reagents for Influenza vaccine standardisation
Reference antigens and antiserum reagents for the standardization of vaccines are produced by the following WHO laboratories:
Essential Regulatory Laboratories (ERL)
National Institute for Biological Standards and Control (NIBSC), UK
Center for Biologics Evaluation and Research (CBER), USA
National Institute for Infectious Disease (NIID), Japan
Therapeutic Goods Administration (TGA), Australia